Bremelanotide for Female Sexual Dysfunctions Responder Analyses From a Phase 2B Dose-Ranging Study

被引：5
|
作者：
DeRogatis, Leonard R. [1 ]
Edelson, Jeffrey [1 ]
Jordan, Robert [1 ]
Greenberg, Sally [1 ]
Portman, David J. [1 ]
机构：
[1] Maryland Ctr Sexual Hlth, Lutherville Timonium, MD USA
来源：
OBSTETRICS AND GYNECOLOGY | 2014年 / 123卷
关键词：
D O I：
10.1097/01.AOG.0000447289.23270.72
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：26S / 27S
页数：2
相关论文
共 50 条
  • [41] A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
    Fraser, Graeme L.
    Lederman, Samuel
    Waldbaum, Arthur
    Kroll, Robin
    Santoro, Nanette
    Lee, Misun
    Skillern, Laurence
    Ramael, Steven
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (04): : 382 - 392
  • [42] Key learnings and the informed design of a randomized, placebo-controlled, dose-ranging phase 2b study to evaluate the efficacy of tezepelumab in moderate-to-severe Atopic Dermatitis
    Komjathy, S.
    Griffiths, J.
    Parnes, J. R.
    ALLERGY, 2020, 75 : 194 - 195
  • [43] A phase II dose-ranging study of histamine dihydrochloride (Maxamine®) and interferon-α-2b as a new therapy for chronic hepatitis C:: 12-week interim analysis
    Lurie, Y
    Beer-Gabel, M
    Malnick, SD
    Hyle, S
    Gehlsen, KR
    JOURNAL OF HEPATOLOGY, 2000, 32 : 104 - 104
  • [44] Responder Analyses Evaluating Treatment Effects Over Time with Gefapixant in a Phase 2b Study of Refractory or Unexplained Chronic Cough
    Morice, A. H.
    McGarvey, L.
    Smith, J.
    Birring, S. S.
    Sher, M. R.
    Wu, W.
    Muccino, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [45] Phase I dose-ranging study of a recombinant human follicle-stimulating hormone (rhFSH) in healthy female volunteers
    Gertz, B.
    Lammerich, A.
    Bias, P.
    HUMAN REPRODUCTION, 2014, 29 : 319 - 320
  • [46] Iscalimab (CFZ533) in Patients with Sjogren's Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
    Fisher, Benjamin A.
    Mariette, Xavier
    Papas, Athena S.
    Grader-Beck, Thomas
    Bootsma, Hendrika
    Ng, Wan-Fai
    Van Daele, Paul
    Finzel, Stephanie
    Elgueta, Sergio
    Hermann, Josef
    McCoy, Sara
    Bookman, Arthur
    Sopala, Monika
    Luo, Wen-Lin
    Scheurer, Cornelia
    Hueber, Wolfgang
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3242 - 3244
  • [47] Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia
    Krause, DS
    Reinhardt, J
    Vazquez, JA
    Reboli, A
    Goldstein, BP
    Wible, M
    Henkel, T
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) : 2021 - 2024
  • [48] Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines: Additional Analyses From a Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Study
    Bertucci, Vince
    Humphrey, Shannon
    Carruthers, Jean
    Solish, Nowell
    Muhn, Channy
    Swift, Arthur
    Rubio, Roman G.
    Shears, Gill
    Rosen, Nathan
    DERMATOLOGIC SURGERY, 2017, 43 : S262 - S273
  • [49] A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
    Glue, P
    Rouzier-Panis, R
    Raffanel, C
    Sabo, R
    Gupta, SK
    Salfi, M
    Jacobs, S
    Clement, RP
    HEPATOLOGY, 2000, 32 (03) : 647 - 653
  • [50] Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
    Ritchlin, Christopher T.
    Kavanaugh, Arthur
    Merola, Joseph F.
    Schett, Georg
    Scher, Jose U.
    Warren, Richard B.
    Gottlieb, Alice B.
    Assudani, Deepak
    Bedford-Rice, Kathy
    Coarse, Jason
    Ink, Barbara
    McInnes, Iain B.
    LANCET, 2020, 395 (10222): : 427 - 440
12345